Damian A. Laber

2.3k total citations · 1 hit paper
76 papers, 1.8k citations indexed

About

Damian A. Laber is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Damian A. Laber has authored 76 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Molecular Biology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Damian A. Laber's work include Cancer Genomics and Diagnostics (8 papers), Platelet Disorders and Treatments (6 papers) and Advanced biosensing and bioanalysis techniques (6 papers). Damian A. Laber is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Platelet Disorders and Treatments (6 papers) and Advanced biosensing and bioanalysis techniques (6 papers). Damian A. Laber collaborates with scholars based in United States, Australia and China. Damian A. Laber's co-authors include Donald M. Miller, John O. Trent, Paula J. Bates, Shelia D. Thomas, Stephanie A. Wagner, Goetz Kloecker, Robert A. Figlin, Andrea Harzstark, Harry A. Drabkin and Gregory W. Smith and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Damian A. Laber

71 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer

2009 696 citations Paula J. Bates, Damian A. Laber et al. Experimental and Molecular Pathology profile →

Peers

Countries citing papers authored by Damian A. Laber

Since Specialization

Citations

This map shows the geographic impact of Damian A. Laber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damian A. Laber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damian A. Laber more than expected).

Fields of papers citing papers by Damian A. Laber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damian A. Laber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damian A. Laber. The network helps show where Damian A. Laber may publish in the future.

Co-authorship network of co-authors of Damian A. Laber

This figure shows the co-authorship network connecting the top 25 collaborators of Damian A. Laber. A scholar is included among the top collaborators of Damian A. Laber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damian A. Laber. Damian A. Laber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Direct Oral Anticoagulants in Budd‐Chiari Syndrome 2024 ·European Journal Of Haematology ·(unknown), (unknown), (unknown), (unknown), Turab Mohammed, Damian A. Laber	1
2	Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera 2024 ·Journal of Clinical Medicine ·Nathan Visweshwar, Bradley S. Fletcher, Michael Jaglal, Damian A. Laber, Ankita Patel, (unknown), (unknown), (unknown), (unknown), A. Manoharan	1
3	Insights into the Impact of Hesitancy on Cancer Care and COVID-19 2023 ·Cancers ·Nathan Visweshwar, (unknown), (unknown), Michael Jaglal, Damian A. Laber, (unknown), Lubomir Sokol, Eduardo M. Sotomayor, A. Manoharan	2
4	Association between Iron Deficiency Anemia and Thrombosis, a Population Based Study 2023 ·Blood ·(unknown), Damian A. Laber	0
5	A Novel Case of Leflunomide-Induced Thrombotic Thrombocytopenic Purpura 2021 ·Journal of Hematology ·Misty Dawn Shields, William Paul Skelton, Damian A. Laber, (unknown), (unknown)	3
6	Evolving paradigm in thrombophilia screening 2019 ·Blood Coagulation & Fibrinolysis ·(unknown), Nathan Visweshwar, Michael Jaglal, Lubomir Sokol, Damian A. Laber	10
7	Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy 2018 ·Anticancer Research ·Min‐Bin Chen, Damian A. Laber	17
8	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy 2017 ·Journal for ImmunoTherapy of Cancer ·Jose Sandoval‐Sus, (unknown), Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim, (unknown)	27
9	Fixed-Dose Every-Other-Week Capecitabine and Oxaliplatin for Refractory Squamous Cell Carcinoma of the Head and Neck 2010 ·The American Journal of the Medical Sciences ·Guilherme Rabinowits, (unknown), Donald M. Miller, Goetz Kloecker, Damian A. Laber	3
10	The Role of Human Papilloma Virus in Lung Cancer: A Review of the Evidence 2009 ·The American Journal of the Medical Sciences ·Arash Rezazadeh, Damian A. Laber, Shin‐je Ghim, (unknown), Goetz Kloecker	46
11	Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer breakdown → 2009 ·Experimental and Molecular Pathology ·Paula J. Bates, Damian A. Laber, Donald M. Miller, Shelia D. Thomas, John O. Trent	696
12	Obtaining Routine Blood Cultures During Interleukin-2-Containing Therapy Is Unnecessary 2009 ·American Journal of Clinical Oncology ·Michael Jaglal, Damian A. Laber, Forest W. Arnold, Donald M. Miller, Jason Chesney, Goetz Kloecker	0
13	IL‐4 production by CD8+ lymphomatoid papulosis, type C, attracts background eosinophils 2008 ·Journal of Cutaneous Pathology ·Stephen P. Slone, Alvin W. Martin, Samuel R. Wellhausen, (unknown), Janine C. Malone, Sheron C. Lear, Damian A. Laber	9
14	Rituximab‐induced interstitial lung disease 2007 ·American Journal of Hematology ·Stephanie A. Wagner, (unknown), Damian A. Laber	101
15	A Phase I study of thalidomide, Capecitabine and temozolomide in advanced cancer 2007 ·Cancer Biology & Therapy ·Damian A. Laber, (unknown), Goetz Kloecker, (unknown), (unknown), Carolina Salvador	8
16	Why Did He Die? 2006 ·Cancer Investigation ·Damian A. Laber	1
17	Cefotetan-induced hemolytic anemia after perioperative prophylaxis 2006 ·American Journal of Hematology ·Carlos Martı́n, Damian A. Laber	4
18	A Phase II Study of Higher Dose Docetaxel in Androgen-Independent Prostate Cancer 2006 ·American Journal of Clinical Oncology ·Damian A. Laber, (unknown), (unknown), (unknown), George H. Goldsmith, (unknown), Renato V. La Rocca	4
19	Etiology of thrombocytopenia in all patients treated with heparin products 2005 ·European Journal Of Haematology ·Damian A. Laber, Carlos Martı́n	12
20	Clinical spectrum of myelophthisis in cancer patients 2004 ·American Journal of Hematology ·(unknown), Damian A. Laber	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact